Integ Inc.

Inverness Medical Technology Inc. 's purchase of struggling diabetes testing start-up LXN Corp. [See Deal] may have surprised industry analysts because of the hefty price tag—roughly $30 million

A look at financing, M&A, and alliance activity in November 2000-February 2001 In this issue we are presenting another installment of our quarterly review of dealmaking—in this case November 2000-Janu

Diabetes glucose monitoring remains a tough field for newcomers, who face competition from four entrenched players. But two of the newer entrants appear to be succeeding. by Wendy Diller Diabetes bloo

Cygnus' volatile history isn't all that unusual for successful device start-ups. So why did it survive when others failed? By Wendy Diller The December 6 meeting of the FDA Clinical Chemistry and Clin